A little further reading on the subject; it is a little techie but oh well. Thanks for being on top of things dub.

Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products

http://link.springer.com/content/pdf/10.1007%2Fs11419-013-0182-9.pdf#page-1

I think I have to call bullshit on this one … AB-Pinaca is safe, it is suspect that ADB-Pinaca would cause this. Contaminated? Mistake in identification? Media hype? Don’t believe everything you read on drugs-forum.

My guess is media hype and couple 16 yrs olds got way higher than they ever been took a trip to the ER cause they cant handle their shit i am not a well trusted or known person around here but i can vouch AB-pinaca is perfectly safe as long as its at least 99% pure….. another educated guess would be that the batch was manufactured wrong…to much acetone ratios messed up or maybe poison batch of RC could be a number of factors……..my opinon is thats what they get for messing with "crazy clown" or anything in a decorated mylar bag probably ordered off alibaba and filled with poison herbs and badly manufactured blends stay away from this type of packaging is my opinon if its not homemade from someone you can trust simply don’t smoke it.

AXA = :wacked:

also the news article he linked on DF.com the reporter called it ADB-Pinaca……… its AB-Pinaca or AB-FUBINACA the news cant even get it right lol

AXA = :wacked:

Not you dub, talking about the sensational news article.

Axa is prob putting banned chems, synthetic opiods and stimulants in his belnds. Why else would he so adamantly deny any problems with these compounds?

I though you stopped blending TB?

———————

I believe the CDC over Axa’s opinion….

Acute Kidney Injury Associated with Synthetic Cannabinoid Use — Multiple States, 2012
Weekly
February 15, 2013 / 62(06);93-98

In March 2012, the Wyoming Department of Health was notified by Natrona County public health officials regarding three patients hospitalized for unexplained acute kidney injury (AKI), all of whom reported recent use of synthetic cannabinoids (SCs), sometimes referred to as "synthetic marijuana." SCs are designer drugs of abuse typically dissolved in a solvent, applied to dried plant material, and smoked as an alternative to marijuana. AKI has not been reported previously in users of SCs and might be associated with 1) a previously unrecognized toxicity, 2) a contaminant or a known nephrotoxin present in a single batch of drug, or 3) a new SC compound entering the market. After the Wyoming Department of Health launched an investigation and issued an alert, a total of 16 cases of AKI after SC use were reported in six states. Review of medical records, follow-up interviews with several patients, and laboratory analysis of product samples and clinical specimens were performed. The results of the investigation determined that no single SC brand or compound explained all 16 cases. Toxicologic analysis of product samples and clinical specimens (available from seven cases) identified a fluorinated SC previously unreported in synthetic marijuana products: (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl) methanone, also known as XLR-11, in four of five product samples and four of six patients’ clinical specimens. Public health practitioners, poison center staff members, and clinicians should be aware of the potential for renal or other unusual toxicities in users of SC products and should ask about SC use in cases of unexplained AKI.

Epidemiologic Findings

The first three patients (Table 1, cases 1–3) reported smoking SCs in the days or hours before symptom onset. Public health staff members interviewed the three and reviewed their medical records. The patients were young, previously healthy males who reported smoking either a blueberry-flavored SC product (one patient) or an unspecified SC product (two patients). They experienced severe nausea, vomiting, and flank or abdominal pain and went to emergency departments during February 26–29. Local law enforcement officials were notified and released a media advisory warning of illness associated with SC use.

The Wyoming Department of Health launched an investigation to identify other cases and determine the cause of illness. A case initially was defined as nausea, vomiting, abdominal or back pain, and AKI (i.e., serum creatinine concentration above the facility’s reference range) in a patient reporting SC use and illness onset during February 1–March 1. Hospital staff members from two regional medical facilities conducted retrospective reviews of emergency department and hospital admission records. The Wyoming Department of Health issued a health alert on March 1 to all licensed health-care providers, hospitals, emergency departments, and urgent-care centers in Wyoming, describing the possible association between AKI and SC use and requesting that potential cases be reported. On March 21, the Wyoming state epidemiologist contacted CDC regarding the first three cases. On March 24, a fourth Wyoming patient became ill after smoking either a blueberry-flavored or bubblegum-flavored SC product and was found to meet the case definition (Table 1, case 4).

A collaboration among several state public health officials, poison center toxicologists, forensic laboratory scientists, individual clinicians, and the Arkansas K2 Research Consortium, identified an additional 12 cases of SC-associated AKI in Oregon (six cases), New York (two), Oklahoma (two), Rhode Island (one), and Kansas (one) in hospitalized patients who had serum creatinine concentration above the facility’s reference range after smoking an SC product during March 16–December 3. CDC medical toxicologists reviewed clinical and laboratory data from all 16 cases (Table 1).

All 16 patients initially visited emergency departments and subsequently were hospitalized. The 16 patients included 15 males aged 15–33 years (median: 18.5 years) and one female aged 15 years; all but one had nausea and vomiting. Twelve patients reported abdominal, flank, and/or back pain. None reported preexisting renal dysfunction or use of medication that might have caused renal problems. The highest serum creatinine concentrations (creatinine peak) among the 16 patients ranged from 3.3 to 21.0 mg/dL (median: 6.7 mg/dL; normal 0.6–1.3 mg/dL) and occurred 1–6 days after symptom onset (median: 3 days). Urinalysis for 15 patients showed variable results: proteinuria (eight patients), casts (five), white blood cells (nine), and red blood cells (eight). Twelve patients underwent renal ultrasonograpy, nine of whom had a nonspecific increase in renal cortical echogenicity; none had hydronephrosis.

Six of eight patients with a renal biopsy demonstrated acute tubular injury, and three of eight patients demonstrated features of acute interstitial nephritis. Kidney function recovery was apparent within 3 days of creatinine peak in most patients. However, five of the 16 patients required hemodialysis, and four patients received corticosteroids; none died. Other infectious, autoimmune, pharmacologic, or other toxic causes of AKI were not found.

Toxicologic Analysis

Of the 16 cases, toxicologic analysis of implicated SC products and clinical specimens was possible in seven (Table 2). No single SC product explained all of the cases. Two SC products recovered by law enforcement officials in Wyoming and epidemiologically linked to cases 1–3 were tested by the Arkansas K2 Research Consortium laboratory (Arkansas K2) and the University of California–San Francisco Clinical and Environmental Toxicology Laboratory (UCSF). Gas chromatography/mass spectrometry (Arkansas K2) and liquid chromatography/time-of-flight mass spectrometry (UCSF) analysis revealed that both products contained 3-(1-naphthoyl) indole, a precursor to several aminoalkylindole synthetic cannabinoids. One of the two product samples also contained the potent synthetic cannabinoid AM2201, which has been linked to human disease and death, but not to AKI.

Standardized liquid chromatography–time of flight mass spectrometry methods validated for trace level analysis of synthetic cannabinoid parent compounds and metabolites were used for all clinical assays (UCSF). A sample of the product smoked by the patient in case 4 contained 3-(1-naphthoyl) indole and XLR-11, a previously undescribed fluorinated-derivative of the SC compound UR-144 currently in circulation. A urine specimen collected from the same patient was positive for the XLR-11 N-pentanoic acid metabolite. A blood specimen from the patient in case 6, who smoked "Phantom Wicked Dreams," contained the N-pentanoic acid metabolite of XLR-11. In case 11, analysis of the SC product "Mr. Happy" and a serum specimen revealed the SCs XLR-11 and UR-144; a urine specimen contained the N-pentanoic acid metabolite of XLR-11. In case 12, samples of "Clown Loyal" were found to contain XLR-11. In cases 13 and 14, analysis of "Lava" and associated clinical specimens identified XLR-11 and the N-pentanoic acid metabolite of XLR-11. In case 15, analysis of "Flame 2.0" was negative for XLR-11. For nine of the 16 cases, neither product samples nor clinical specimens were available for analysis.

Reported by
Tracy D. Murphy, MD, Kelly N. Weidenbach, MPH, Clay Van Houten, MS, Wyoming Dept of Health. Roy R. Gerona, PhD, Dept of Laboratory Medicine, Univ of California–San Francisco. Jeffery H. Moran, PhD, Arkansas Public Health Laboratory, Arkansas Dept of Health. Ronald I. Kirschner, MD, Nebraska Regional Poison Center. Jeanna M. Marraffa, PharmD, Christine M. Stork, PharmD, Upstate Medical Univ, Upstate New York Poison Center; Guthrie S. Birkhead, MD, Andie Newman, DVM, New York State Dept of Health. Robert G. Hendrickson, MD, B. Zane Horowitz, MD, Oregon Poison Center; Karen Vian, Douglas County Public Health; Richard F. Leman, MD, Oregon Public Health Div. Stephen L. Thornton, MD, Univ of Kansas Hospital Poison Control Center; Clayton Wood, DO, Dept of Emergency Medicine, Univ of Kansas Hospital. David A. Myers, MD, Oklahoma Univ Health Sciences Center. Erik Orr, MS, Geospatial Research, Analysis, and Services Program, John J. Devlin, MD, Michael D. Schwartz, MD, Office of Environmental Health Emergencies, National Center for Environmental Health; Genevieve L. Buser, MD, EIS Officer, CDC. Corresponding contributor: Michael D. Schwartz, mschwartz@cdc.gov, 770-488-7282.

Editorial Note
Synthetic cannabinoid compounds originally were developed to facilitate study of cannabinoid receptor pharmacology, but in recent years have emerged as drugs of abuse. In 2005, SC products marketed as "Spice" first emerged in European countries, before appearing in the United States in 2009, where they were marketed initially as "K2." Today, SC products are distributed worldwide under countless trade names and packaged in colorful wrappers designed to appeal to teens, young adults, and first-time drug users (1). Products often are packaged with disingenuous labels such as "not for human consumption" or "incense," but health professionals and legal authorities are keenly aware that these products are smoked like marijuana. Despite federal and state regulations to prohibit SC sale and distribution, illicit use continues, and reports of illness are increasing (1–4).

The expectation of a more intense high than that induced by marijuana, easy access, affordability, and avoidance of detection by many commonly used urine drug tests all contribute to the growing abuse of SCs, especially among male adolescents (1,5). The increasing use of SCs by young persons, coupled with mounting evidence of adverse health effects, has led to state and federal legislation (3,6). However, full recognition of the potential dangers of SCs is not widespread among users or sellers, and SC products remain available on the Internet and at many convenience stores. Further, differences in state drug enforcement statutes have led to different laws and approaches to drug enforcement (7).

Although related to delta-9-tetrahydrocannabinol, the active ingredient in marijuana, SCs are two to three times more likely to be associated with sympathomimetic effects (i.e., tachycardia and hypertension), and approximately five times more likely to be associated with hallucinations (8). In addition, an increase in the occurrence of seizures has been reported with SC use (9). This report describes unanticipated AKI with SC abuse. Given the rapidity with which new SC compounds enter the marketplace and their increasing use in the past 3 years, outbreaks of unexpected toxicity associated with their use are likely to increase.

Management of suspected SC toxicity is symptomatic and supportive; no antidote exists. All of the patients in this report recovered creatinine clearance during their hospital stay, although the length of time was variable; one patient was discharged before his creatinine normalized. However, a risk for long-term kidney sequelae might exist. Recent studies suggest an increased risk for chronic and end-stage renal disease following AKI of various etiologies, despite initial recovery (10). Physicians caring for otherwise healthy adolescents and young adults with unexplained AKI should inquire about SC use, and cases of suspected SC poisoning should be reported to both the regional poison center and the appropriate state health department. Regional poison centers can be reached by telephone at 1-800-222-1222, from anywhere in the United States.

In this report, the product used by five of the 16 patients, including two patients (cases 13 and 14) who used the same product, contained a novel fluorinated SC (XLR-11). In addition, XLR-11 and/or XLR-11 metabolites were found in five of the seven cases for whom clinical specimens were available. XLR-11 emerged on the SC market in the first half of 2012; therefore, experience with this fluorinated compound has been limited. The consistent finding of XLR-11 in product samples and clinical specimens has alternative explanations. XLR-11, a metabolite, or a contaminant associated with it might be responsible for AKI in these patients, or its presence might simply reflect the widespread use of this particular compound in SC products during the study period rather than a causal association with AKI. Health-care providers should be aware of renal and other unexpected toxicities from use of SC products, especially with newer SC compounds.

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6206a1.htm?s_cid=mm6206a1_w

Of the 16 cases, toxicologic analysis of implicated SC products and clinical specimens was possible in seven (Table 2). No single SC product explained all of the cases. Two SC products recovered by law enforcement officials in Wyoming and epidemiologically linked to cases 1–3 were tested by the Arkansas K2 Research Consortium laboratory (Arkansas K2) and the University of California–San Francisco Clinical and Environmental Toxicology Laboratory (UCSF). Gas chromatography/mass spectrometry (Arkansas K2) and liquid chromatography/time-of-flight mass spectrometry (UCSF) analysis revealed that both products contained 3-(1-naphthoyl) indole, a precursor to several aminoalkylindole synthetic cannabinoids. One of the two product samples also contained the potent synthetic cannabinoid AM2201, which has been linked to human disease and death, but not to AKI.

just to start off this came from the CDC you said it yourself its obviously copied and pasted….. so lets start off with this "No single SC product explained all of the cases." and not much else needs to be said after this "One of the two product samples also contained the potent synthetic cannabinoid AM2201, which has been linked to human disease and death, but not to AKI."………….yea AM-2201 killing people i smoked it for over a year im in perfect health

its not even a 5-fluro version no chance of fluoroacetate poisoning and no offense but how can you say that vendors are poisoning people when the long term and even some short term effects are unknown ive been spiced for over 3-4 years and im in perfect health

Axa is prob putting banned chems, synthetic opiods and stimulants in his belnds. Why else would he so adamantly deny any problems with these compounds?

I though you stopped blending TB?

———————

I believe the CDC over Axa’s opinion….

Acute Kidney Injury Associated with Synthetic Cannabinoid Use — Multiple States, 2012
Weekly
February 15, 2013 / 62(06);93-98

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6206a1.htm?s_cid=mm6206a1_w

Dude, you are completely wrong and you owe me an apology. The CDC report you posted is old news and has no relevance to the topic which concerns the possible new chem ‘ADB-Pinaca’. Wikipedia does not even have an entry yet for ‘ADB-Pinaca’ and the CDC has not released its findings on the Geogia and Colorado cases yet. I am unfamiliar with ADB-Pinaca but find it strange that a minor modification to the AB-Pinaca molecule could cause problems. Lots of posts all over the net about AB-Pinaca, search for yourself. I suspect the Georgia lab, I do not think they are telling the whole story.

Sorry Axa, didn’t mean to come off as a total dick.

No problem, thanks for the apology.

another educated guess would be that the batch was manufactured wrong……..

This.. I would imagine they were making AB-Pinaca, and somehow frogged it up.
Apparently these vendors don’t test their shit, and would count my chickens that the blend vendors using this didn’t either.

to much acetone ratios messed up or maybe poison batch of RC could be a number of factors.

Acetone I highly doubt has anything to do with this, considering the batch was already contaminated before blenders got it.

Poison is a better way to look at it, especially when synthesized wrong  :wacked:
Please do tests you lab rats!!

also the news article he linked on DF.com the reporter called it ADB-Pinaca……… its AB-Pinaca or AB-FUBINACA the news cant even get it right lol

They were just naming the compound found within the blend. I’m pretty sure they are aware of the current SC’s available, so I really doubt that was a ‘typo’.

Refer back to my above comments, as I say bad/wrong synthesis was the case here if I had to guess.

_______________

XLR-11, aka 5f-UR-144 though I would have to agree has some long term effects, unfortunately. Just as dub’s article that was pasted shows some health issues. Not going to sit here and deny it, but I do not have anything bad to say about all the previous ones before this one. No side effects that I have known or heard of, but for someone using XLR-11 for over a year will start to see what I am talking about. Very unfortunate, but it is the truth.

That is why is was taken off of some chem sites so early, even before the ban. They knew….
All the others were still being sold though. This is the reason why. FYI.

Yes I aint blended since I became ill.  I just remember pinnacle stood out to me.  Fuck a blend is my mentality anymore.  The vendors are hurting ppl and they know it.

I honestly don’t think when you became ill it was all because of blends. I’m not going to say that wasn’t the cause, but correlation does not imply causation. At all. Were you using a specific blend heavily?

I wouldn’t think vendors are knowingly hurting people, but if anyone if would be the main main guys that would even have a clue rather than further down the tier. Think about it, most vendors are using there own product, or at least using their own compounds to an extent. I would hope that they don’t know anything just as most don’t. But they do know what compound they are using (specifically) and more than likely does research on it quite a bit.

just to start off this came from the CDC you said it yourself its obviously copied and pasted….. so lets start off with this "No single SC product explained all of the cases." and not much else needs to be said after this "One of the two product samples also contained the potent synthetic cannabinoid AM2201, which has been linked to human disease and death, but not to AKI."………….yea AM-2201 killing people i smoked it for over a year im in perfect health

I hate to say but this doesn’t mean everyone will be perfect in health as you will. Think of a peanut allergy; Someone that doesn’t know they even have one and eats a peanut butter sandwich. FUCKED. Could cause death, but not necessarily.

People are allergic to these noids just like anyone can be allergic to anything. Dub had a bad fit from 5f-pb22. One would bet he is allergic.
I’m not allergic to anything that I know of. Never had any problems with ANY noids. Guessing you are the same way as well then!

its not even a 5-fluro version no chance of fluoroacetate poisoning and no offense but how can you say that vendors are poisoning people when the long term and even some short term effects are unknown ive been spiced for over 3-4 years and im in perfect health

True, very true nothing is known of these, especially long term effects.

Over the past 3-4 years, compounds have been coming and going like hotcakes. Doubt you would be a good case study for a single compound used for that long, but I see what you are saying though. SC’s in general are not bad at all, and not even the slightest bit harmless when used in moderation. It’s particular ones that are having problems, unfortunately.

Axa is prob putting banned chems, synthetic opiods and stimulants in his belnds. Why else would he so adamantly deny any problems with these compounds?

I though you stopped blending TB?

———————

I believe the CDC over Axa’s opinion….

Acute Kidney Injury Associated with Synthetic Cannabinoid Use — Multiple States, 2012
Weekly
February 15, 2013 / 62(06);93-98

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6206a1.htm?s_cid=mm6206a1_w

Dude, you are completely wrong and you owe me an apology. The CDC report you posted is old news and has no relevance to the topic which concerns the possible new chem ‘ADB-Pinaca’. Wikipedia does not even have an entry yet for ‘ADB-Pinaca’ and the CDC has not released its findings on the Geogia and Colorado cases yet. I am unfamiliar with ADB-Pinaca but find it strange that a minor modification to the AB-Pinaca molecule could cause problems. Lots of posts all over the net about AB-Pinaca, search for yourself. I suspect the Georgia lab, I do not think they are telling the whole story.

I wouldn’t think that it being modified like that would cause an outbreak of problems that fast. But obviously it has, and long term effects aren’t even in play here with this one. I still think that it was synthesized wrong, or something in that nature (contaminated, etc) and sold anyways for obvious reasons, cha-ching!

If it was AB-Pinaca, I seriously doubt any of this would have happened, as you know I’m sure.
Lot of reports as said too, with none of these illnesses following. Coincidence? I think not.

Slight modification could do a lot of damage apparently. Another way to determine this would be all of the commercials on TV starting out with "Have you or a loved one been using…..". "If so, you may be entitled to a giant lump sum of money!!". These are more than likely because of slight modifications to other pharmaceuticals, and no long term studies being done.. So it’s possible that this was the whole case here too.

_____________

TL:DR;  Horrible AB-Pinaca synthesis > ZERO tests ran to determine validity (or didn’t GAF!) > Sold to domestic source > ZERO tests ran to determine validity > Used in blends > These reports.

smoking random herbs is just as bad as anything in spice. get good base herbs for starters. if vendors sell sticks and junk, run away.